In a filing, Roivant Sciences Ltd revealed its Officer Venker Eric acquired Company’s shares for reported $4.17 million on Dec 09 ’25. In the deal valued at $20.85 per share,200,000 shares were bought.
Then, MANCHESTER KEITH S sold 1,300,000 shares, generating $26,304,500 in total proceeds. Upon selling the shares at $20.23, the Director now owns 18,047,727 shares.
Before that, Gold Daniel Allen sold 1,300,000 shares. Roivant Sciences Ltd shares valued at $26,304,500 were divested by the Director at a price of $20.23 per share. As a result of the transaction, Gold Daniel Allen now holds 18,047,727 shares, worth roughly $368.72 million.
Citigroup initiated its Roivant Sciences Ltd [ROIV] rating to a Buy in a research note published on September 02, 2025; the price target was $16. Wolfe Research began covering ROIV with “an Outperform” recommendation on February 15, 2024. Piper Sandler started covering the stock on January 05, 2024. It rated ROIV as “an Overweight”.
Price Performance Review of ROIV
On Tuesday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock fall -2.67% to $20.43. Over the last five days, the stock has gained 1.64%. Roivant Sciences Ltd shares have risen nearly 69.12% since the year began. Nevertheless, the stocks have risen 72.70% over the past one year. While a 52-week high of $21.48 was reached on 12/08/25, a 52-week low of $8.73 was recorded on 04/07/25.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 20.15, which if violated will result in even more drops to 19.88. On the upside, there is a resistance level at 20.94. A further resistance level may holdings at 21.46.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-11-14, dropping by -2.22 million shares to a total of 23.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 25.27 million shares. There was a decline of -9.64%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
